Regeneron to gain exclusive rights to signature medicine from French collaborator

Times Union | Albany

Jun 4, 2022

Regeneron has entered into an amended agreement with Sanofi Biotechnology that will allow it to exclusively develop and commercialize certain immuno-oncology products. |!| Albany